Sunday, March 12, 2017 9:06:32 PM
3 Ways to profit from this...
1. $17 Billion dollar buyout in 2014 - Mitragyna speciosa (known as kratom) had a brief omnipresence on Wall Street until Fall 2014 when Sigma-Aldrich Corporation, a U.S. based bio-tech company that developed kratom alkaloid solutions was quickly acquired by Merck Group (Merck KGaA), a German big pharm company for $17 billion. Could HADV be next?
2. $125/share for closest competitor GW Pharmaceuticals (NASDAQ: GWPH) , a developer for plant-derived cannabinoid therapeutics. GW Pharmaceuticals has successfully developed [Sativex] the world's first prescription medicine made from the cannabis plant. OTC: HADV is currently under $0.20/share
3. Health Advance (ORC HADV) poised to be the first medical food approved by the FDA on the GRAS list.
RECENT NEWS Link: Recent News Click Here
Stock Research/Quote Current Stock Quote click here
$gwph $hadv
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM